My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
VistaGen Therapeutics (VTGN)
VTGN nasdaq
United States
VistaGen Therapeutics

VistaGen Therapeutics Stock Analysis & Ratings

VistaGen Therapeutics Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The VistaGen Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


VTGN Stock Stats

Previous Close$2.11
Bid0 x 0
Ask0 x 0
Today’s Range$1.94 - $2.11
52-Week Range$0.67 - $3.55
Average Volume1.09M
Market Cap$407.39M
P/E Ratio-4.4
Earnings DateFeb 14, 2022

Company Description

VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Shawn K. Singh
343 Allerton Avenue, South San Francisco, CA, 94080, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.67 and its highest was $3.55 in the past 12 months.
    What is VistaGen Therapeutics’s market cap?
    VistaGen Therapeutics’s market cap is $407.39M.
      What is VistaGen Therapeutics’s price target?
      The average price target for VistaGen Therapeutics is $7.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $5.00. The average price target represents 243.14% Increase from the current price of $2.04.
        What do analysts say about VistaGen Therapeutics?
        VistaGen Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is VistaGen Therapeutics’s upcoming earnings report date?
          VistaGen Therapeutics’s upcoming earnings report date is Feb 14, 2022 which is in 79 days.
            How were VistaGen Therapeutics’s earnings last quarter?
            VistaGen Therapeutics released its earnings results on Nov 10, 2021. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.012.
              Is VistaGen Therapeutics overvalued?
              According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
                Does VistaGen Therapeutics pay dividends?
                VistaGen Therapeutics does not currently pay dividends.
                What is VistaGen Therapeutics’s EPS estimate?
                VistaGen Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does VistaGen Therapeutics have?
                VistaGen Therapeutics has 199,700,000 shares outstanding.
                  What happened to VistaGen Therapeutics’s price movement after its last earnings report?
                  VistaGen Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went up 0.429%.
                    Which hedge fund is a major shareholder of VistaGen Therapeutics?
                    Currently, no hedge funds are holding shares in VTGN

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis